Clinical trials: Placebo Response
Infant
Effects of follow-on Formula Enriched on Short-chain Fructooligosaccharides (scFOS) on Immune Response in Healthy Infants
In this study the investigators hypothesized that the chronic intake of fructo-oligosaccharides would increase fecal immunoglobulin A (IgA) specific to poliovirus vaccination and bifidobacteria in infants.
- Trial name
- NCT00948051
- Testing
- Follow-on formula supplemented with fructo-oligosaccharides
- Where
- Spain
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Syral
Rheumatoid Arthritis (RA)
TLL-018 in Patients With Moderate to Severe Active Rheumatoid Arthritis With Inadequate Response or Intolerance to csDMARDs
This is a randomized, double-blind, placebo-controlled parallel-group Phase II study. The study aims to evaluate the efficacy and safety of TLL-018 in adult patients with moderate to severe active rheumatoid arthritis who have…
- Trial name
- NCT07748728
- Testing
- TLL-018
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Hangzhou Highlightll Pharmaceutical Co., Ltd
Autism Spectrum Disorder
Effects of Intranasal Administration of a Single Dose of Oxytocin Using a Novel Device in Adults With Autism Spectrum Disorder
Oxytocin (OT) is a small, naturally occurring peptide currently in clinical use to stimulate lactation in breastfeeding women. The intranasal administration of OT has recently attracted attention as a potential novel treatment in…
- Trial name
- NCT02414503
- Testing
- 8IU intranasal oxytocin, 24IU intranasal oxytocin, OptiNose Breath Powered Bi
- Where
- Norway
- Volunteers
- 17 people
- Sponsor
- OptiNose AS
Attention Deficit/ Hyperactivity Disorder
A Study to Evaluate Effectiveness and Safety of Prolonged Release OROS Methylphenidate in Adults With Attention Deficit Hyperactivity Disorder
The purpose of this study is to evaluate the efficacy of 2 fixed dosages of Prolonged Release (PR) OROS methylphenidate (54 and 72 mg/day) compared with placebo in adult patients with attention deficit/hyperactivity disorder…
- Trial name
- NCT00714688
- Testing
- prolonged release (PR) OROS methylphenidate 54 mg, prolonged release (PR) OROS methylphenidate 72 mg
- Where
- 42 sites in Belgium, Denmark and 9 more
- Volunteers
- 279 people
- Sponsor
- Janssen-Cilag International NV
Rheumatoid Arthritis
A Study to Evaluate the Safety and Efficacy of MabThera (Rituximab) in Combination With Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Who Failed on Anti-Tumor Necrosis Factor Alpha Therapy
This study will assess the safety and efficacy of rituximab combined with MTX in participants with active rheumatoid arthritis (RA) who have had an inadequate response to anti-Tumor Necrosis (TNF) alpha therapy.
- Trial name
- NCT00468546
- Testing
- MabThera/Rituxan, Methotrexate
- Where
- 115 sites in United States, Belgium and 9 more
- Volunteers
- 520 people
- Sponsor
- Hoffmann-La Roche
Sepsis
GR270773 In The Treatment Of Suspected Or Confirmed Gram-Negative Severe Sepsis In Adults
The primary objective is to estimate the size of the GR270773 treatment effect on 28-day all-cause mortality for two doses of GR270773 versus placebo in adult subjects with suspected or confirmed Gram-negative severe sepsis.
- Trial name
- NCT00089986
- Testing
- Intravenous GR270773- Phospholipid Emulsion
- Where
- 390 sites in United States, Argentina and 32 more
- Volunteers
- 1,415 people
- Sponsor
- GlaxoSmithKline
Rheumatoid Arthritis
Study to Assess Efficacy of Tacrolimus + Methotrexate Versus Placebo + Methotrexate in Treatment of Rheumatoid Arthritis
The purpose of this study is to evaluate the efficacy of the combination of tacrolimus + methotrexate compared to methotrexate alone in the treatment of the signs and symptoms of rheumatoid arthritis over 6 months in patients…
- Trial name
- NCT00036153
- Testing
- Tacrolimus (Prograf®), Methotrexate
- Where
- 45 sites in United States, Canada
- Volunteers
- 210 people
- Sponsor
- Astellas Pharma Inc
Rheumatoid Arthritis, DMARD-naive and Early Disease Patients
A Study of the EP4 Antagonist CR6086 in Combination With Methotrexate, in DMARD-naïve Patients With Early Rheumatoid Arthritis
CR6086 is a new, potent and selective, orally available, small molecule prostaglandin EP4 receptor antagonist, endowed with immunomodulatory properties.
- Trial name
- NCT03163966
- Testing
- CR6086, Methotrexate
- Where
- Czechia
- Volunteers
- 248 people
- Sponsor
- Rottapharm Biotech
Primary Nocturnal Enuresis
Desmopressin Response in the Young
The purpose of this study is to determine whether desmopressin administered as a melt tablet is effective in reducing the number of wet nights in children and adolescents who suffer from bedwetting.
- Trial name
- DRY (NCT00230594)
- Testing
- desmopressin
- Where
- 9 sites in Canada
- Volunteers
- 132 people
- Sponsor
- Ferring Pharmaceuticals
Acute Heart Failure
Hemodynamic Responses to RLX030 Infusion in Subjects With Acute Heart Failure
This study will assess the hemodynamic effect of RLX030 infusion in subjects with acute heart failure. In addition safety and effects on renal function and biomarkers will be assessed.
- Trial name
- NCT01543854
- Testing
- RLX030
- Where
- 20 sites in Argentina, Germany and 4 more
- Volunteers
- 71 people
- Sponsor
- Novartis Pharmaceuticals
Rheumatoid Arthritis
A Study of Tocilizumab Plus Non-biological DMARD in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Non-biological DMARDs
This randomized, double-blind, placebo-controlled study will use Magnetic Resonance Imaging (MRI) to assess the efficacy of tocilizumab plus non-biological DMARD in patients with moderate to severe rheumatoid arthritis who have…
- Trial name
- NCT01034397
- Testing
- tocilizumab [RoActemra/Actemra], non-biological DMARDs
- Where
- 11 sites in Portugal
- Volunteers
- 54 people
- Sponsor
- Hoffmann-La Roche
Type 2 Diabetes
Dose Response Study in Japanese Patients
This is a 12-week study to determine the effect on glucose and lipids, safety, and tolerability of four doses of tesaglitazar (0.25, 0.5, 0.75 and 1 mg) compared with placebo in patients with type 2 diabetes.
- Trial name
- NCT00261417
- Testing
- Tesaglitazar
- Where
- 20 sites in Japan
- Volunteers
- 250 people
- Sponsor
- AstraZeneca
Influenza
Phase II Study to Investigate the Kinetics of the Immune Response Generated by Influenza Virus Vaccine.
The primary objective of this study was to perform a variety of assays on blood, serum, nasal wash and cell samples obtained from healthy adult subjects for the purposes of developing assays for application in the further…
- Trial name
- NCT00192309
- Testing
- CAIV-T, TIV
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Primary Biliary Cholangitis
Study to Evaluate the Efficacy and Safety of K-808 (Pemafibrate) in Participants With Primary Biliary Cholangitis (PBC) With Inadequate Response to Ursodeoxycholic Acid (UDCA) and/or Obeticholic Acid (OCA) Treatment.
Study to investigate the efficacy and safety of two doses of K-808 (pemafribate) in subjects with PBC.
- Trial name
- NCT06247735
- Testing
- K-808 (Dose A), K-808 (Dose B)
- Where
- 38 sites in United States, Canada and 1 more
- Volunteers
- 46 people
- Sponsor
- Kowa Research Institute, Inc.
Hypertension
A Study to Evaluate the Efficacy and Safety of Eplerenone in the Treatment of Hypertension in Children.
To evaluate the efficacy, safety, and toleration of eplerenone in the treatment of children aged 6 to 16 years with high blood pressure. The study will last approximately 10 weeks and about 320 patients will participate.
- Trial name
- NCT00147589
- Testing
- Eplerenone
- Where
- 41 sites in United States, Dominican Republic and 3 more
- Volunteers
- 320 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Chronic Plaque Psoriasis
Multiple-loading Dose Regimen Study in Patients With Chronic Plaque-type Psoriasis
Loading dose, four arm, double-blind, parallel group, placebo-controlled study comparing single and multiple doses of AIN457 to placebo in patients with a diagnosis of moderate to severe chronic plaque psoriasis.
- Trial name
- NCT00805480
- Testing
- AIN457
- Volunteers
- 130 people
- Sponsor
- Novartis Pharmaceuticals
HIV Infections
The Safety and Effectiveness of PMPA Prodrug in HIV-Infected Patients
To evaluate the safety of single and multiple doses (28 daily doses) of 9-[2-(R)-[[bis[[(isopropoxycarbonyl)- oxy]methoxy]phosphinoyl]methoxy]propyl]adenine fumarate (PMPA) prodrug administered orally to HIV-infected patients.
- Trial name
- NCT00002396
- Testing
- Tenofovir disoproxil fumarate
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Gilead Sciences
Pain, Postoperative Pain
Dose-Response Study of MR-107A-01 in The Treatment of Post-Surgical Dental Pain
MR-107A-01 is being studied to investigate its efficacy, safety, and dose-response after dental surgery.
- Conditions
- Pain, Postoperative Pain, Pain, Acute
- Trial name
- NCT04571515
- Testing
- MR-107A-01
- Where
- United States
- Volunteers
- 114 people
- Sponsor
- Mylan Inc.
Asthma
Study to Evaluate the Potential Effect of Benralizumab on the Humoral Immune Response to the Seasonal Influenza Vaccination in Adolescent and Young Adult Patients With Severe Asthma
This is a randomized, double-blind, parallel group, placebo-controlled study designed to investigate the potential effect of a fixed dose of benralizumab administered subcutaneously (SC) on antibody responses following seasonal…
- Trial name
- ALIZE (NCT02814643)
- Testing
- Benralizumab, Seasonal influenza virus vaccine
- Where
- 24 sites in United States
- Volunteers
- 103 people
- Sponsor
- AstraZeneca
Rheumatoid Arthritis
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Not Responding.
The purpose of the study is to evaluate the effectiveness of two dosing regimens of fostamatinib compared to placebo, in patients with rheumatoid arthritis (RA) who are taking methotrexate but not responding.
- Trial name
- OSKIRA - 1 (NCT01197521)
- Testing
- fostamatinib
- Where
- 127 sites in United States, Argentina and 15 more
- Volunteers
- 923 people
- Sponsor
- AstraZeneca